Stock listing
NASDAQ:MREO Mereo BioPharma Group plc Stock
Home listing (NASDAQ) of Mereo BioPharma Group plc
Follow Mereo BioPharma Group plc into a list and get an email when it puts out news.
Share price · NASDAQ:MREO
$0.26 USD -0.03 (-10.1%)
Close on Nov 20, 2026
- Day range
- $0.26 – $0.277 USDNov 20, 2026
- Volume
- 1.08M sharesNov 20, 2026
- Market cap
- $41.52M USDAt the close on Nov 20, 2026 · price × 159.7M shares outstanding
- 52-week range
- $0.20 – $2.37 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $378,995 USDMedian day 1.04M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:MREO · Home | $0.26 USD | -0.029 (-10.1%) | 1,081,184 | $0.275 | $0.277 | $0.26 | $0.289 | Close on Nov 20, 2026 |
| LSE:0A9G | $0.266 USD | -0.014 (-5.2%) | 9,908 | $0.278 | $0.278 | $0.263 | $0.280 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:MREO · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.26 | -0.029 | -10.1% | $0.275 | $0.277 | $0.26 | 1,081,184 | |
| $0.289 | +0.015 | +5.4% | $0.266 | $0.30 | $0.266 | 859,631 | |
| $0.275 | -0.03 | -10.0% | $0.301 | $0.305 | $0.265 | 1,037,251 | |
| $0.305 | -0.003 | -0.8% | $0.298 | $0.307 | $0.297 | 625,526 | |
| $0.308 | +0.003 | +0.8% | $0.302 | $0.318 | $0.297 | 893,672 | |
| $0.305 | -0.002 | -0.5% | $0.297 | $0.313 | $0.29 | 698,057 | |
| $0.307 | +0.009 | +2.9% | $0.299 | $0.31 | $0.299 | 387,887 | |
| $0.298 | +0.003 | +0.9% | $0.287 | $0.304 | $0.28 | 1,774,949 | |
| $0.295 | +0.012 | +4.3% | $0.287 | $0.305 | $0.285 | 1,724,752 | |
| $0.283 | +0.003 | +0.9% | $0.271 | $0.285 | $0.271 | 655,613 | |
| $0.28 | -0.023 | -7.5% | $0.30 | $0.313 | $0.277 | 925,396 | |
| $0.303 | +0.012 | +4.2% | $0.297 | $0.307 | $0.281 | 529,606 | |
| $0.291 | +0.001 | +0.3% | $0.289 | $0.298 | $0.285 | 272,436 | |
| $0.29 | 0.00 | 0.0% | $0.286 | $0.299 | $0.28 | 477,594 | |
| $0.29 | -0.012 | -4.0% | $0.297 | $0.315 | $0.28 | 543,700 | |
| $0.302 | +0.005 | +1.7% | $0.30 | $0.325 | $0.287 | 1,134,100 | |
| $0.297 | +0.005 | +1.7% | $0.281 | $0.303 | $0.281 | 113,600 | |
| $0.292 | +0.017 | +6.2% | $0.286 | $0.299 | $0.278 | 291,300 | |
| $0.275 | -0.007 | -2.5% | $0.279 | $0.287 | $0.275 | 313,200 | |
| $0.282 | -0.005 | -1.7% | $0.281 | $0.287 | $0.275 | 519,000 | |
| $0.287 | -0.004 | -1.4% | $0.288 | $0.294 | $0.283 | 381,700 | |
| $0.291 | -0.004 | -1.4% | $0.301 | $0.314 | $0.289 | 330,000 | |
| $0.295 | -0.007 | -2.3% | $0.308 | $0.318 | $0.294 | 488,400 | |
| $0.302 | -0.001 | -0.3% | $0.31 | $0.32 | $0.30 | 530,900 | |
| $0.303 | -0.006 | -1.9% | $0.301 | $0.309 | $0.293 | 722,300 | |
| $0.309 | -0.001 | -0.3% | $0.30 | $0.32 | $0.297 | 529,300 | |
| $0.31 | -0.01 | -3.1% | $0.31 | $0.323 | $0.30 | 890,200 | |
| $0.32 | +0.005 | +1.6% | $0.311 | $0.321 | $0.297 | 1,267,900 | |
| $0.315 | -0.035 | -10.0% | $0.35 | $0.364 | $0.31 | 1,329,200 | |
| $0.35 | -0.025 | -6.7% | $0.38 | $0.388 | $0.343 | 1,222,300 | |
| $0.375 | +0.022 | +6.2% | $0.35 | $0.383 | $0.341 | 1,063,600 | |
| $0.353 | +0.003 | +0.9% | $0.355 | $0.367 | $0.346 | 1,133,600 | |
| $0.35 | -0.038 | -9.8% | $0.398 | $0.399 | $0.35 | 1,269,000 | |
| $0.388 | +0.008 | +2.1% | $0.37 | $0.403 | $0.363 | 2,470,300 | |
| $0.38 | +0.013 | +3.5% | $0.385 | $0.389 | $0.361 | 880,400 | |
| $0.367 | -0.035 | -8.7% | $0.399 | $0.401 | $0.364 | 1,602,500 | |
| $0.402 | +0.029 | +7.8% | $0.37 | $0.423 | $0.37 | 3,067,200 | |
| $0.373 | +0.003 | +0.8% | $0.366 | $0.392 | $0.361 | 1,549,700 | |
| $0.37 | 0.00 | 0.0% | $0.371 | $0.381 | $0.355 | 1,744,300 | |
| $0.37 | +0.032 | +9.5% | $0.334 | $0.372 | $0.33 | 2,095,400 | |
| $0.338 | -0.002 | -0.6% | $0.345 | $0.349 | $0.325 | 1,305,900 | |
| $0.34 | +0.024 | +7.6% | $0.318 | $0.373 | $0.313 | 3,921,500 | |
| $0.316 | +0.026 | +9.0% | $0.291 | $0.32 | $0.291 | 2,320,600 | |
| $0.29 | -0.013 | -4.3% | $0.303 | $0.31 | $0.289 | 1,929,700 | |
| $0.303 | +0.013 | +4.5% | $0.28 | $0.31 | $0.28 | 2,739,800 | |
| $0.29 | +0.024 | +9.0% | $0.269 | $0.297 | $0.268 | 1,744,800 | |
| $0.266 | -0.019 | -6.7% | $0.281 | $0.29 | $0.261 | 1,519,000 | |
| $0.285 | +0.005 | +1.8% | $0.28 | $0.29 | $0.271 | 886,700 | |
| $0.28 | 0.00 | 0.0% | $0.28 | $0.289 | $0.272 | 1,185,900 | |
| $0.28 | +0.035 | +14.3% | $0.26 | $0.293 | $0.26 | 5,109,900 | |
| $0.245 | +0.002 | +0.8% | $0.243 | $0.249 | $0.24 | 699,500 | |
| $0.243 | -0.012 | -4.7% | $0.256 | $0.256 | $0.239 | 2,951,200 | |
| $0.255 | +0.005 | +2.0% | $0.25 | $0.259 | $0.245 | 803,800 | |
| $0.25 | -0.022 | -8.1% | $0.272 | $0.272 | $0.248 | 1,333,000 | |
| $0.272 | +0.005 | +1.9% | $0.264 | $0.28 | $0.263 | 876,900 | |
| $0.267 | -0.01 | -3.6% | $0.27 | $0.284 | $0.263 | 805,000 | |
| $0.277 | +0.01 | +3.7% | $0.27 | $0.288 | $0.27 | 1,559,200 | |
| $0.267 | +0.014 | +5.5% | $0.253 | $0.288 | $0.253 | 1,311,000 | |
| $0.253 | -0.019 | -7.0% | $0.266 | $0.274 | $0.252 | 1,556,500 | |
| $0.272 | -0.006 | -2.2% | $0.288 | $0.288 | $0.267 | 1,421,700 | |
| $0.278 | -0.004 | -1.3% | $0.289 | $0.289 | $0.276 | 1,017,000 | |
| $0.282 | -0.008 | -2.7% | $0.288 | $0.293 | $0.281 | 1,154,252 | |
| $0.29 | -0.001 | -0.2% | $0.29 | $0.294 | $0.285 | 799,385 | |
| $0.29 | -0.003 | -1.0% | $0.303 | $0.306 | $0.29 | 714,700 | |
| $0.293 | -0.019 | -6.1% | $0.308 | $0.308 | $0.293 | 754,700 |
- Ticker
- NASDAQ:MREO
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 9, 2026
Mereo BioPharma Reports Third Quarter 2026 Financial Results
Latest deck · November 2026
Investor Presentation (November 2026)
Investor deck · 49 slides
Latest news
Mereo BioPharma Reports Third Quarter 2026 Financial Results
Nov 9, 2026
Closed $0.295 (+4.3%) on Nov 9, 2026
Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights
Mar 19, 2026
Closed $0.361 (+2.6%) on Mar 19, 2026
Mereo BioPharma Group plc on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 2 in the last 12 months · 2 in all · newest Nov 9, 2026 · oldest 2026
- Decks
- 36 decks · latest November 2026
Where Mereo BioPharma Group plc is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:MREO · Home listing · This page | NASDAQ | United States | USD |
| LSE:0A9G | LSE | United Kingdom | USD |
Valuation
EV/sales 20.0× against a median of 17.1×: 3rd lowest of 4 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $16.00M USD
- P/E
- Loss
- EV/sales
- 20.0×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.8×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.34
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Mereo BioPharma Group plc · NASDAQ:MREO | US$41.52M | US$16.00M | n/a | 20.0× | n/a | 1.8× | n/a | 0.0× | 1.34 |
| Spero Therapeutics, Inc. · NASDAQ:SPRO | US$43.23M | −US$63.10M | n/a | −1.5× | n/a | 55.4× | −71.0% | 2.0× | 1.68 |
| Eloxx Pharmaceuticals, Inc. · NASDAQ:ELOX | US$43.15M | −US$1.28M | n/a | n/a | n/a | 1.1× | n/a | 0.3× | n/a |
| Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBP | US$42.45M | −US$68.98M | n/a | n/a | n/a | 0.5× | n/a | 0.1× | 1.85 |
| Arecor Therapeutics PLC · LSE:AREC | US$42.37M | US$38.32M | 48.8× | 17.1× | n/a | 8.8× | 38.7% | 0.0× | n/a |
| OS Therapies Incorporated · AMEX:OSTX | US$42.00M | US$41.57M | n/a | n/a | n/a | n/a | n/a | n/a | 1.70 |
| Advagene Biopharma Co., Ltd. · TPEX:6709 | US$41.89M | US$32.03M | n/a | n/a | n/a | 3.9× | n/a | 0.0× | n/a |
| Biomea Fusion, Inc. · NASDAQ:BMEA | US$41.75M | US$15.85M | n/a | n/a | n/a | 5.5× | n/a | 0.1× | 1.14 |
| Prescient Therapeutics Limited · ASX:PTX | US$41.64M | US$35.80M | n/a | n/a | n/a | 4.4× | n/a | 0.0× | n/a |
| Elicio Therapeutics, Inc. · NASDAQ:ELTX | US$41.05M | US$19.78M | n/a | n/a | n/a | 2.2× | n/a | 0.5× | 1.81 |
| MiNK Therapeutics, Inc. · NASDAQ:INKT | US$40.93M | US$33.46M | n/a | 167× | n/a | n/a | n/a | n/a | 0.81 |
| Median of the others | US$41.94M | US$25.90M | 48.8× | 17.1× | 4.2× | −16.1% | 0.1× | 1.69 |
Forecasts
4 strong buy · 1 buy · 2 hold · 1 sell · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 1.96 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.044 · 5 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Denise Scots-Knight | Chief Executive Officer |
| Christine Fox | Chief Financial Officer |
| Charles Sermon | General Counsel and Business Development |
| Bal Lally | Vice President, Head of HR |
| Bharti Navsariwala | Vice President, Head of Regulatory Affairs |
| Bo Kara | Senior Vice President, Head of Pharmaceutical Development |
| Jackie Parkin | Senior Vice President, Therapeutic Head |
| Ogün Sazova | Vice President, Clinical Development and Medical Affairs |
| John Lewicki | Chief Scientific Officer |
| Wills Hughes-Wilson | Chief Patient Access and Commercial Planning |
Board
| Director | Role |
|---|---|
| Michael Wyzga | Chairman of the Board |
| Anders Ekblom | Non-Executive Director |
| Daniel Shames | Non-Executive Director |
| Deepa Pakianathan | Non-Executive Director |
| Jeremy Bender | Non-Executive Director |
| Justin Roberts | Non-Executive Director |
| Marc Yoskowitz | Non-Executive Director |
| Pierre Jacquet | Non-Executive Director |
Events
- Next results
- Mar 18, 2027 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 9, 2026 · Before open | +4.3% |
| Q2 2026 | Aug 11, 2026 · Before open | +12.5% |
| Q1 2026 | Apr 1, 2026 | −3.0% |
| Q4 2025 | Mar 19, 2026 · Before open | +2.6% |
| Q3 2025 | Nov 10, 2025 · After close | +5.7% |
| Q2 2025 | Aug 12, 2025 · Before open | +9.2% |
| Q1 2025 | May 13, 2025 · Before open | −7.2% |
| Q4 2024 | Mar 26, 2025 | +2.5% |
| Q3 2024 | Nov 12, 2024 · Before open | −4.2% |
| Q2 2024 | Aug 13, 2024 · Before open | +1.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 15, 2024 · After close | +3.1% |
| Q4 2023 | Mar 27, 2024 | +11.9% |
| Q3 2023 | Nov 17, 2023 · After close | +5.3% |
| Q2 2023 | Sep 7, 2023 · Before open | +1.8% |
| Q1 2023 | May 31, 2023 | +3.8% |
| Q4 2022 | Mar 28, 2023 · After close | −2.4% |
| Q3 2022 | Nov 1, 2022 · After close | −7.0% |
| Q4 2021 | Mar 30, 2022 · After close | +7.7% |
| Quarter to Jun 30, 2021 | Aug 11, 2021 | −9.6% |
| Quarter to Mar 31, 2021 | Jun 2, 2021 | +4.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 49 slides | November 2026 |
| Investor Presentation (October 2026) | Investor deck | 49 slides | October 2026 |
| Investor Presentation (May 2026) | Investor deck | 52 slides | May 2026 |
| J.P. Morgan Conference (January 2026) | Conference | 26 slides | Jan 12, 2026 |
| Investor Presentation (January 2025) | Investor deck | 50 slides | January 2025 |
| Investor Presentation (November 2024) | Investor deck | 54 slides | November 2024 |
| Investor Presentation (October 2024) | Investor deck | 52 slides | October 2024 |
| Investor Presentation (August 2024) | Investor deck | 47 slides | August 2024 |
| Investor Presentation (March 2024) | Investor deck | 52 slides | March 2024 |
| Investor Presentation (January 2024) | Investor deck | 50 slides | January 2024 |
All 36 decks
IPO
Withdrawn on Feb 21, 2019. Filed with the SEC to go public on Mar 23, 2018.
- Shares offered
- 15,892,917 ordinary shares
- Underwriters
- Cowen, BMO Capital Markets, RBC Capital Markets, JMP Securities, Cantor Fitzgerald Europe · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Dec 1, 2017 |
| Filed publicly | Mar 23, 2018 |
| Amended once | Apr 9, 2018 |
| Filing withdrawn | Feb 21, 2019 |
Filings
| Filing | Filed |
|---|---|
| RW · Request to withdraw a registration | Feb 21, 2019 |
| CERT · Exchange's certificate of listing | Apr 18, 2018 |
| 8-A12B · Registration of shares for listing on an exchange | Apr 9, 2018 |
| F-1/A · Registration statement, amended | Apr 9, 2018 |
| F-1 · Registration statement | Mar 23, 2018 |
| DRS/A · Draft registration statement, amended | Mar 14, 2018 |
| DRS/A · Draft registration statement, amended | Feb 27, 2018 |
| DRS/A · Draft registration statement, amended | Jan 18, 2018 |
| DRS · Draft registration statement | Dec 1, 2017 |
Open IPO · From the cover of the amended prospectus (F-1/A) filed Apr 9, 2018
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 500.0K | 0 | 10.0M | 0 | 49.2M | 393.0K | -122.0K | 0 | -3.29M | 0 |
| Cost of revenue | 133.0K | 1.09M | 2.57M | 24.2M | 2.05M | 2.01M | 22.7M | 34.6M | 24.6M | |
| Gross profit | 367.0K | -1.09M | 7.43M | 25.0M | -2.05M | -2.01M | -22.7M | -37.9M | -24.6M | |
| Research and development | 17.8M | 20.9M | 17.4M | 29.5M | 31.8M | 21.0M | 30.1M | 22.7M | 34.6M | 24.6M |
| Selling, general and administrative | 23.0M | 26.4M | 18.4M | 21.5M | 21.2M | 15.9M | 12.5M | 10.7M | 11.6M | |
| Operating income | -40.1M | -47.4M | -28.4M | -54.4M | -28.3M | -48.2M | -50.4M | -35.2M | -45.3M | -36.2M |
| Depreciation and amortization | 157.0K | 143.0K | 171.0K | 181.0K | 866.5K | 2.05M | 2.01M | 37.8K | 36.1K | 32.9K |
| EBITDA | -40.0M | -47.2M | -28.2M | -54.2M | -27.4M | -46.1M | -48.4M | -35.2M | -45.3M | -36.1M |
| Interest expense | 255.0K | 1.37M | 2.88M | 4.17M | 5.22M | 6.38M | 3.50M | 2.36M | 1.09M | 179.8K |
| Income before tax | -41.9M | -43.3M | -30.0M | -42.9M | 19.2M | -213.4M | -52.5M | -37.3M | -47.0M | -33.7M |
| Income tax | 0 | 0 | -532.0K | -718.0K | 2.05M | -3.62M | -8.00M | -5.28M | -8.15M | -5.33M |
| Net income | -41.9M | -43.3M | -29.5M | -42.2M | 17.2M | -209.8M | -44.5M | -32.0M | -38.8M | -28.4M |
| Earnings per share, basic | -0.05 | -0.06 | -0.04 | -0.07 | 0.15 | -3.10 | -2.49 | -2.25 | -2.81 | -0.63 |
| Earnings per share, diluted | -0.05 | -0.06 | -0.04 | -0.07 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 41.0M | 69.8M | 57.4M | 68.2M | 126.7M | 31.3M | 20.9M | 25.0M | 50.0M | 53.6M |
| Short-term investments | 769.5K | 748.0K | 720.6K | 2.50M | 2.50M | 0 | ||||
| Receivables | 1.98M | 3.25M | 3.73M | 1.42M | 1.02M | 12.0M | 5.89M | 509.4K | 6.10M | |
| Inventory | 1.25M | -1.82M | -4.64M | -12.0M | -293.3K | -2.50M | -53.9M | |||
| Current assets | 45.0M | 74.8M | 63.8M | 75.2M | 134.3M | 40.7M | 40.3M | 34.5M | 63.2M | 60.8M |
| Property, plant and equipment | 137.0K | 257.0K | 405.0K | 551.0K | 2.53M | 1.57M | 11.6M | 149.0K | 153.4K | 173.9K |
| Goodwill | 0 | 0 | 0 | |||||||
| Total assets | 45.9M | 76.4M | 66.5M | 77.4M | 171.0M | 86.1M | 114.5M | 67.3M | 96.3M | 86.8M |
| Accounts payable | 1.33M | 2.44M | 2.35M | 3.49M | 3.09M | 4.33M | 8.14M | 5.57M | 2.64M | 3.21M |
| Current liabilities | 4.30M | 13.8M | 9.49M | 24.4M | 17.0M | 11.7M | 39.6M | 16.2M | 9.62M | 3.21M |
| Long-term debt | 4.39M | 14.4M | 16.1M | 5.37M | 14.6M | 18.8M | 3.13M | |||
| Total debt | 202.0K | 6.43M | 5.95M | 22.7M | 24.5M | 42.9M | 21.5M | 20.8M | 3.13M | |
| Total liabilities | 5.00M | 15.4M | 16.0M | 26.0M | 51.9M | 106.6M | 61.2M | 34.5M | 33.9M | 7.51M |
| Shareholders' equity | 40.9M | 61.0M | 50.5M | 51.4M | 119.0M | -20.5M | 53.3M | 32.8M | 62.5M | 79.3M |
| Shares outstanding | 798.5M | 798.5M | 798.1M | 795.0M | 116.7M | 67.8M | 17.9M | 14.2M | 13.8M | 44.8M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -31.0M | -32.8M | -21.1M | -48.8M | -7.07M | -38.6M | -60.2M | -23.1M | -32.1M | -27.4M |
| Capital spending | -20.0K | 0 | 0 | -13.0K | -722.1K | -21.8K | -27.5K | -35.5K | -2.30M | -3.47K |
| Free cash flow | -31.0M | -32.8M | -21.1M | -48.8M | -7.79M | -38.6M | -60.3M | -23.2M | -34.4M | -27.4M |
| Cash from investing | -20.0K | -699.0K | -419.0K | 1.99M | -568.2K | 2.04M | 56.8M | 251.6K | -3.74M | 372.6K |
| Cash from financing | 327.0K | 46.1M | 7.97M | 200.0K | 104.8M | 47.3M | -7.49M | -2.07M | 33.7M | 68.4M |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Share buybacks | 0 | 0 | -1.31M | -306.8K | 15.0M | 67.9M | ||||
| Change in cash | -30.7M | 12.4M | -10.8M | -46.6M | 95.6M | 9.71M | -11.4M | -25.0M | -3.53M | 41.3M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 9, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 28, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 19, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2026 | Results | SEC |
| 8-K · Current report | Aug 11, 2026 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 14, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | May 14, 2026 | Meeting outcome | SEC |
| 8-K/A · Current report, amended | May 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2026 | Acquisition or disposal | SEC |
| ARS · Annual report to shareholders | Apr 9, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 9, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Mar 27, 2026 | Meeting notice | SEC |
| 8-K · Current report | Mar 27, 2026 | Management or board change | SEC |
| 10-K · Annual report | Mar 19, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 19, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 17, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Feb 2, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 12, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 9, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 6, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Dec 29, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 10, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 10, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| 8-K · Current report | Jul 10, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 11, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 14, 2025 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 12, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 8, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 8, 2025 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 4, 2025 | Big-stake notice | SEC |
| 10-K · Annual report | Mar 26, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 26, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jan 23, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 13, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Dec 6, 2024 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Dec 5, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Dec 4, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Dec 3, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 2, 2024 | Other filings | SEC |
| S-3 · Registration statement | Nov 25, 2024 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| 4 · Change in ownership | Sep 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 13, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 12, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 12, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 12, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 12, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 12, 2024 | Other filings | SEC |
| 4 · Change in ownership | Aug 23, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 22, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Jul 11, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2024 | Insider trade | SEC |
| 144/A · Notice of proposed sale, amended | Jun 24, 2024 | Other filings | SEC |
| 144/A · Notice of proposed sale, amended | Jun 24, 2024 | Other filings | SEC |
| 144/A · Notice of proposed sale, amended | Jun 24, 2024 | Other filings | SEC |
| 144/A · Notice of proposed sale, amended | Jun 24, 2024 | Other filings | SEC |
| 144/A · Notice of proposed sale, amended | Jun 24, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 20, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 20, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 20, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 20, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 20, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Jun 17, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 14, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Jun 14, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 11, 2024 | Current report | SEC |
| 4/A · Change in ownership, amended | Jun 11, 2024 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | May 28, 2024 | Other filings | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 23, 2024 | Other filings | SEC |
| 8-K · Current report | May 23, 2024 | Meeting outcome | SEC |
| CORRESP · Letter to the SEC | May 21, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 20, 2024 | Other filings | SEC |
| S-3 · Registration statement | May 15, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | May 15, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2024 | Results | SEC |
| ARS · Annual report to shareholders | Apr 24, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 24, 2024 | Meeting notice | SEC |
| SC 13D/A · Big-stake notice, amended | Apr 16, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Apr 15, 2024 | Material contract | SEC |
| 10-K · Annual report | Mar 27, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 27, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 6, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 5, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jan 23, 2024 | Offer document | SEC |
| 8-K · Current report | Jan 8, 2024 | Current report | SEC |
| 3 · Initial statement of ownership | Jan 2, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 2, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 2, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 2, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 2, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 2, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 2, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 2, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 2, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 2, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 2, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 2, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 2, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 2, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 2, 2024 | Insider trade | SEC |
| 8-A12B/A · Registration of shares for listing on an exchange, amended | Dec 18, 2023 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Dec 18, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 29, 2023 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 20, 2023 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Nov 16, 2023 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 15, 2023 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 13, 2023 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 8, 2023 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 6, 2023 | Big-stake notice | SEC |
This page holds 200 of 441 filings. Open Filings
Cap table
Built by 6ix from Mereo BioPharma Group plc’s releases
- Common shares
- 159,690,973
- Fully diluted
- 159,690,973
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 159,690,973 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 159,690,973 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Annalisa Jenkins Other companies: Skye Bioscience, Inc. (Director · Since at least Feb 29, 2024); COMPASS Pathways Plc (Director · Since at least Jan 1, 2022); Serina Therapeutics, Inc. (Director · Nov 27, 2018 – Jun 21, 2021 · Past); Tectonic Therapeutic, Inc. (Director · Jun 20, 2018 – Jun 6, 2023 · Past); Dimension Therapeutics (President and CEO, Director · Oct 21, 2015 – Nov 7, 2017 · Past); Ardelyx, Inc. (Director · Apr 20, 2015 – Jun 13, 2019 · Past) | Director · Since at least Jan 1, 2024 |
| Jeremy Bender Other companies: Bicara Therapeutics Inc. (Director · Since at least Jul 28, 2026); Aura Biosciences, Inc. (Director · Since at least Jul 7, 2026); Day One Biopharmaceuticals Inc (CHIEF EXECUTIVE OFFICER, Director · Since at least May 26, 2021); Fusion Pharmaceuticals Inc (Director · Oct 16, 2023 – Jun 4, 2024 · Past) | Non-Executive Director · Since at least Jan 1, 2024 |
| Michael Wyzga Other companies: X4 Pharmaceuticals, Inc. (Director · Since at least Jun 9, 2025); Tvardi Therapeutics, Inc. (Board Member · Since at least Apr 15, 2025) | Director · Since at least Feb 26, 2026 |
| Justin H. Roberts Other companies: TherapeuticsMD, Inc. (Board Member · Since at least Aug 23, 2022) | Non-Executive Director · Since at least Jan 1, 2024 |
| Pierre Jacquet Other companies: EXACT Sciences Corporation (Director · Jun 9, 2022 – Jun 8, 2023 · Past) | Non-Executive Director · Since at least Jan 1, 2024 |
| Anders Ekblom | Non-Executive Director · Since at least Nov 5, 2026 |
| Bal Lally | Vice President, Head of HR · Since at least Nov 4, 2026 |
| Bharti Navsariwala | Vice President, Head of Regulatory Affairs · Since at least Nov 4, 2026 |
| Bo Kara | Senior Vice President, Head of Pharmaceutical Development · Since at least Nov 4, 2026 |
| Charles Sermon | General Counsel and Business Development · Since at least Jan 1, 2024 |
All 19 people
| Person | Seat |
|---|---|
| Christine Fox | Chief Financial Officer · Since at least Jan 1, 2024 |
| Daniel Shames | Non-Executive Director · Since at least Nov 5, 2026 |
| Deepa Pakianathan | Non-Executive Director · Since at least Nov 5, 2026 |
| Denise Scots-Knight | Chief Executive Officer · Since at least Mar 19, 2026 |
| Jackie Parkin | Senior Vice President, Therapeutic Head · Since at least Nov 4, 2026 |
| John Lewicki | Chief Scientific Officer · Since at least Nov 4, 2026 |
| Marc Yoskowitz | Non-Executive Director · Since at least Nov 5, 2026 |
| Ogün Sazova | Vice President, Clinical Development and Medical Affairs · Since at least Nov 4, 2026 |
| Wills Hughes-Wilson | Chief Patient Access and Commercial Planning · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Mereo BioPharma Group plc.